LABELS · ead30b86-564f-7e78-e053-2a95a90ab41c

Depo-Medrol

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2022-10-12
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS ) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).

Full extracted label fields

application numbers

NDA011757

boxed warning exact

brand names

Depo-Medrol

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

generic names

METHYLPREDNISOLONE ACETATE

ead30b86-564f-7e78-e053-2a95a90ab41c

indications and usage exact

INDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS ) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).

indications and usage tables exact

is original packager

manufacturer names

Asclemed USA, Inc.

matched search terms

cancer
lymphomas
tumor
tumors

package ndcs

76420-081-01

product ndcs

76420-081

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRA-ARTICULAR
INTRALESIONAL
INTRAMUSCULAR
SOFT TISSUE

rxcuis

1743855
1743856

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 224
end exclusive: true
exact text: INDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condi
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 0

current approval status

not_reconciled

duplicate text group

dup-f2d2e58f1a3c4ab41431

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-f5148354e0abb5859fb8

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 24
end exclusive: true
exact text: INDICATIONS AND USAGE A.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 2 · positive indication candidate

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 812
end exclusive: true
exact text: INDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 0

current approval status

not_reconciled

duplicate text group

dup-145e0b137fe5e304052e

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-1c9575848b1c34451fe9

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

end: 306
end exclusive: true
exact text: is indicated
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 294

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 612
end exclusive: true
exact text: For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 25

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 3 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 979
end exclusive: true
exact text: ate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 413

current approval status

not_reconciled

duplicate text group

dup-71a691722f345c2647a3

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-c36f190a9b919d29550d

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 779
end exclusive: true
exact text: Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 613

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1363
end exclusive: true
exact text: sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) he
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 580

current approval status

not_reconciled

duplicate text group

dup-747162b4c523515493c3

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-35ce48ee66bd959ce9c4

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1163
end exclusive: true
exact text: Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 780

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1514
end exclusive: true
exact text: rticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 964

current approval status

not_reconciled

duplicate text group

dup-e315c636c3659495b030

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-acd56fc535f2d48adea2

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1314
end exclusive: true
exact text: Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 1164

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1714
end exclusive: true
exact text: sociated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemot
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 1115

current approval status

not_reconciled

duplicate text group

dup-e9432d861e149a2265c6

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-79d2c16e677c2fccec41

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1514
end exclusive: true
exact text: Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 1315

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1921
end exclusive: true
exact text: Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tum
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 1315

current approval status

not_reconciled

duplicate text group

dup-e238b17d597a4979032e

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-7a681e54a7871dae6181

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1721
end exclusive: true
exact text: Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 1515

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1998
end exclusive: true
exact text: aneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arter
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 1522

current approval status

not_reconciled

duplicate text group

dup-464afadd8118d1ceae4a

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-b7e4121f6d3b7af0e358

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1798
end exclusive: true
exact text: Neoplastic Diseases : For palliative management of: leukemias and lymphomas.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 1722

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2138
end exclusive: true
exact text: eningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of p
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 1599

current approval status

not_reconciled

duplicate text group

dup-bfe4996da675278fca6f

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-3057bf2127928febc7ff

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

context exact
ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
kind
biomarker
polarity
not_inferred
span
end
1937
end exclusive
true
exact text
metastatic brain tumor or craniotomy
label id
ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start
1901
context exact
ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
kind
stage_or_setting
polarity
not_inferred
span
end
1937
end exclusive
true
exact text
metastatic brain tumor or craniotomy
label id
ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start
1901

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1938
end exclusive: true
exact text: Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 1799

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2284
end exclusive: true
exact text: es : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated p
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 1739

current approval status

not_reconciled

duplicate text group

dup-cb0ee41fe2d925e62766

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-7113d67516c48f14e1dc

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2084
end exclusive: true
exact text: Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 1939

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2418
end exclusive: true
exact text: with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, sympto
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 1885

current approval status

not_reconciled

duplicate text group

dup-fa04153d63cdfb28cf42

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-1da8629b331d0cb58a65

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2218
end exclusive: true
exact text: Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 2085

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2636
end exclusive: true
exact text: inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing sp
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 2019

current approval status

not_reconciled

duplicate text group

dup-a5edfccf9ad763cdaf9b

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-d894890e9f7f69a4ff2c

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2436
end exclusive: true
exact text: Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 2219

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2988
end exclusive: true
exact text: es : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS ) DEPO-MEDROL is indicated as adjunctive thera
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 2237

current approval status

not_reconciled

duplicate text group

dup-87fde2dbd863f05e3d08

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-5b23f0ae0ea2e1ca8876

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2788
end exclusive: true
exact text: Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 2437

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3074
end exclusive: true
exact text: hritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS ) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerb
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 2589

current approval status

not_reconciled

duplicate text group

dup-720395f11fdcddf6e991

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-4a6592603744f1de1de8

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2874
end exclusive: true
exact text: For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 2789

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 15 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3077
end exclusive: true
exact text: oid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS ) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbati
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 2675

current approval status

not_reconciled

duplicate text group

dup-da5bac15cc6f6b30a2a3

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-e66268d782517a94edd3

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2877
end exclusive: true
exact text: B.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 2875

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 16 · positive indication candidate

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3434
end exclusive: true
exact text: arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS ) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions o
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 2678

current approval status

not_reconciled

duplicate text group

dup-c7fe4cf6ebad404a0147

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-c6bfe1731639d067bbe0

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

end: 2968
end exclusive: true
exact text: is indicated
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 2956

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3234
end exclusive: true
exact text: For Intra-articular Or Soft Tissue Administration (See WARNINGS ) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 2878

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 17 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3437
end exclusive: true
exact text: atient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of g
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 3035

current approval status

not_reconciled

duplicate text group

dup-60264bec3ecd7e116342

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-74bb1097f32b6ea834cd

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3237
end exclusive: true
exact text: C.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 3235

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 18 · positive indication candidate

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3659
end exclusive: true
exact text: ent over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 3038

current approval status

not_reconciled

duplicate text group

dup-0d6048e643cf75fe7515

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-7259ce25da8aeb6ddae8

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

end: 3295
end exclusive: true
exact text: is indicated
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 3283

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3572
end exclusive: true
exact text: For Intralesional Administration DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum.
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 3238

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 19 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3659
end exclusive: true
exact text: s, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 3373

current approval status

not_reconciled

duplicate text group

dup-e968b55544805c82065c

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-aa2992ecfb862732c0dd

label id

ead30b86-564f-7e78-e053-2a95a90ab41c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3659
end exclusive: true
exact text: DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).
label id: ead30b86-564f-7e78-e053-2a95a90ab41c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5f1e7978237a3669594c0dccf7c0648c8fb13590cdf1fc2814ad4aeed2e09770
start: 3573

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ead30b86-564f-7e78-e053-2a95a90ab41c%22

spl effective date

2022-10-12

spl set id

cb0e1c92-d2df-47f8-ab3f-edc1a98bf4b6

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice